← Back to Clinical Trials
Recruiting Phase 4 NCT06570187

NCT06570187 The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06570187
Status Recruiting
Phase Phase 4
Sponsor Cairo University
Condition Sepsis
Study Type INTERVENTIONAL
Enrollment 128 participants
Start Date 2024-10-01
Primary Completion 2026-10

Trial Parameters

Condition Sepsis
Sponsor Cairo University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 128
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2024-10-01
Completion 2026-10
Interventions
DexmedetomidinePropofol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This clinical trial aims to evaluate the effect of dexmedetomidine in Sepsis-Associated Acute Kidney Injury in critically ill patients by answering the following questions: 1. What is dexmedetomidine's effect on kidney functions? 2. What is the safety and efficacy of dexmedetomidine in Sepsis-Associated Acute Kidney Injury? The investigator will compare dexmedetomidine to the standard sedative. The Participant will take either dexmedetomidine or the standard sedative during their hospitalization, with follow-up of the following: 1. Vital signs including blood pressure, body temperature, respiratory rate, heart rate, and oxygen saturation. 2. Laboratory data including kidney function tests, electrolytes, complete blood count, and liver function tests. 3. An electrocardiogram will be followed to check the heart's electrical activity. 4. The level of alertness or agitation to avoid over and under-sedation. 5. The level of organ dysfunction and mortality risks. 6. Duration of mechanical ventilation. 7. Duration of hospitalization.

Eligibility Criteria

Inclusion Criteria: * Age \>21 years old * Patients with sepsis who develop AKI within 48 hours during ICU stay * Need for sedation due to the need for mechanical ventilation (MV) (both invasive and non- invasive) within 48 hours of AKI Exclusion Criteria: * Contraindications to dexmedetomidine including any of the following: severe bradycardia (heart rate (HR) \< 50 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block unless a pacemaker is inserted * Acute myocardial ischemia * Mean arterial blood pressure \< 50 mmHg despite adequate resuscitation and vasopressor therapy at the time of enrollment * Pregnancy or lactation * Duration of dexmedetomidine infusion \< 24 hours * Severe valvular heart disease * Active seizures during this ICU admission requiring benzodiazepines * Proven or suspected traumatic brain injury, intracranial hemorrhage, stroke, or spinal cord injury

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology